 |
|
|
| |
Efficacy and Safety of Telaprevir-based Regimens in Cirrhotic Patients with HCV Genotype 1 and Prior Peginterferon/Ribavirin Treatment Failure: Subanalysis of the REALIZE Phase III Study
|
| |
| |
Reported by Jules Levin
AASLD Nov 5-9 2011 SF
S Pol,1 S Roberts,2 P Andreone,3 Z Younossi,4 M Diago,5 EJ Lawitz,6 R Focaccia,7
GR Foster,8 A Horban,9 I Lonjon-Domanec,10 R DeMasi,11 R van Heeswijk,12
S De Meyer,12 G Picchio,11 J Witek,11 S Zeuzem13
1Universite Paris Descartes, INSERM Unité 1016, and Assistance Publique-Hopitaux de Paris, Cochin Hospital, Paris, France; 2Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia; 3Università di Bologna, Bologna, Italy; 4Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 5Hospital General de Valencia, Valencia, Spain; 6Alamo Medical Research, San Antonio, TX, USA; 7Emilio Ribas Infectious Diseases Institute, São Paulo, Brazil; 8Queen Marys University of London, Institute of Cell and Molecular Science, London, UK; 9Medical University of Warsaw, Wolska, Warsaw, Poland; 10Janssen Pharmaceuticals, Paris, France; 11Tibotec Inc., Titusville, NJ, USA; 12Tibotec BVBA, Beerse, Belgium; 13Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
|
| |
|
|
|
|
|
